Manufacturing roundup: Finnish pharma Orion investing $30M+ to boost production; Biosyngen opens new Singapore facility

The Finnish phar­ma­ceu­ti­cal com­pa­ny Ori­on is plan­ning to in­vest around €30 mil­lion ($32.7 mil­lion) to boost its pro­duc­tion ca­pac­i­ty.

Ac­cord­ing to a re­lease, this in­vest­ment will fo­cus on in­creas­ing the pro­duc­tion of in­halers at its plant in Es­poo, Fin­land; ac­tive phar­ma­ceu­ti­cal in­gre­di­ents in Han­ko; and pack­ag­ing at its man­u­fac­tur­ing site in Sa­lo.  The in­vest­ments will start this year and are ex­pect­ed to be fin­ished in 2026.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN